TTOO vs. BIOL, IONM, SDCCQ, GMVDF, SONX, VRAYQ, AFIB, NMRD, UTRS, and MOTS
Should you be buying T2 Biosystems stock or one of its competitors? The main competitors of T2 Biosystems include BIOLASE (BIOL), Assure (IONM), SmileDirectClub (SDCCQ), G Medical Innovations (GMVDF), Sonendo (SONX), ViewRay (VRAYQ), Acutus Medical (AFIB), Nemaura Medical (NMRD), Minerva Surgical (UTRS), and Motus GI (MOTS). These companies are all part of the "medical equipment" industry.
T2 Biosystems vs. Its Competitors
T2 Biosystems (NASDAQ:TTOO) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.
BIOLASE has a consensus target price of $0.40, indicating a potential upside of 0.00%. Given BIOLASE's stronger consensus rating and higher possible upside, analysts clearly believe BIOLASE is more favorable than T2 Biosystems.
BIOLASE has higher revenue and earnings than T2 Biosystems.
T2 Biosystems has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, BIOLASE has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.
23.2% of T2 Biosystems shares are held by institutional investors. Comparatively, 8.8% of BIOLASE shares are held by institutional investors. 0.0% of T2 Biosystems shares are held by insiders. Comparatively, 0.3% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
BIOLASE has a net margin of -41.65% compared to T2 Biosystems' net margin of -563.16%. T2 Biosystems' return on equity of 0.00% beat BIOLASE's return on equity.
In the previous week, BIOLASE had 2 more articles in the media than T2 Biosystems. MarketBeat recorded 2 mentions for BIOLASE and 0 mentions for T2 Biosystems. BIOLASE's average media sentiment score of 0.38 beat T2 Biosystems' score of 0.00 indicating that BIOLASE is being referred to more favorably in the news media.
Summary
BIOLASE beats T2 Biosystems on 11 of the 13 factors compared between the two stocks.
Get T2 Biosystems News Delivered to You Automatically
Sign up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TTOO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
T2 Biosystems Competitors List
Related Companies and Tools
This page (NASDAQ:TTOO) was last updated on 9/13/2025 by MarketBeat.com Staff
Free TTOO Stock Alerts